Full text is available at the source.
Abstract
Cell-based therapies have shown promising results in treating hematological malignancies, but challenges limit their application to other cancers.
- Numerous hurdles, including relapsed disease and a hostile tumor microenvironment, restrict the use of cell-based therapies beyond B cell malignancies.
- Recent advancements in cell engineering and tumor microenvironment modulation may enable broader application of these therapies.
- Innovations in gene editing and cell engineering are addressing longstanding challenges in cancer treatment.
- A review of prominent therapies like CAR-T cells, tumor-infiltrating lymphocytes, and natural killer cells highlights their potential in clinical trials.
- Emerging cell types and combination strategies are being analyzed for their future roles in cancer treatments.
Simplified